- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | HCW Biologics regains Nasdaq compliance, plans stock split | 1 | Investing.com | ||
| 30.06. | HCW Biologics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 30.06. | HCW Biologics Inc.: HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter | 129 | GlobeNewswire (Europe) | MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative... ► Artikel lesen | |
| 26.06. | HCW Biologics Commences 1-for-6 Reverse Stock Split | 1 | RTTNews | ||
| 26.06. | HCW Biologics executes 1-for-6 reverse stock split for Nasdaq | 2 | Investing.com | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.06. | HCW Biologics Inc.: HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 | 303 | GlobeNewswire (Europe) | Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements... ► Artikel lesen | |
| 18.06. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 16.06. | Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss | 1 | Benzinga.com | ||
| 16.06. | HCW Biologics Inc.: HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata | 225 | GlobeNewswire (Europe) | Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants... ► Artikel lesen | |
| 15.06. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.06. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 01.06. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | HCW Biologics takes back rights to commercial-ready reagents | 2 | Seeking Alpha | ||
| 27.05. | HCW Biologics regains ex vivo rights to CAR-T therapy reagents | 1 | Investing.com | ||
| 27.05. | HCW Biologics Inc.: HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen | 1 | GlobeNewswire (USA) | ||
| 22.05. | HCW Biologics raises $4 million in private placement | 1 | Investing.com | ||
| 21.05. | HCW Biologics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.05. | HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules | 5 | GlobeNewswire (USA) | ||
| 15.05. | Why Is HCW Biologics Stock Gaining Today? | 7 | Benzinga.com |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 0,971 | -1,32 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,603 | -3,72 % | ACHTUNG bei InflaRx NV: Der Kurs nähert sich einer gefährlichen Marke - Das sollten Sie jetzt wissen | ||
| INTELLIA THERAPEUTICS | 9,990 | -3,57 % | Wolfe Research stuft Intellia Aktie wegen Bewertungsbedenken herab | ||
| IBIO | 1,301 | +9,79 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 6,670 | +2,46 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 63,88 | +2,40 % | This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | ||
| IMMATICS | 8,520 | +3,59 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,552 | +0,23 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 13,085 | -0,42 % | IMMUNIC, INC. - 8-K, Current Report | ||
| IOVANCE BIOTHERAPEUTICS | 4,345 | +6,76 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,100 | -3,23 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| GENPREX | 7,670 | -4,12 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS3724463027 Genprex Inc. 15.07.2026 US3724464017 Genprex Inc. 16.07.2026 Tausch 22:1 ► Artikel lesen | |
| MACROGENICS | 3,640 | +0,55 % | MacroGenics Completes $122.5 Million Sale Of GMP Manufacturing Operations To Bora Pharmaceuticals | ||
| MESOBLAST | 1,528 | -7,79 % | Wenn die großen Pharmakonzerne Milliarden in Krebs investieren - entsteht der nächste Zelltherapie-Boom ganz woanders? |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,25 %) liegt der Kurs bei 4,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.